All News
Filter News
Found 5,252 articles
-
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
11/7/2023
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the third quarter of 2023.
-
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
11/6/2023
Adverum Biotechnologies, Inc. today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023.
-
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
11/6/2023
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced results from the Phase 2 clinical study evaluating the “extra-strength” 40U dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), the only neurotoxin dedicated exclusively to aesthetics.
-
Revance to Participate in Upcoming Investor Conferences - November 6, 2023
11/6/2023
Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences.
-
Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors
11/6/2023
Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the appointment of David Nicholson, Ph.D., as an independent member of its Board of Directors.
-
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
11/1/2023
CollPlant Biotechnologies announced that the U.S. Patent and Trademark Office has granted a patent that covers CollPlant's photocurable dermal filler product candidate, being developed for the aesthetics market.
-
Aptatek BioSciences, Inc. Appoints Seasoned Healthcare Executive Lee McCracken to its Board of Directors
11/1/2023
Aptatek BioSciences, Inc. has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director.
-
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
11/1/2023
Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market.
-
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
10/31/2023
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”) today announced Phase 2 interim results for CYB003, its proprietary deuterated psilocybin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo.
-
Lexicon Strengthens Management Team With Two New Executives
10/31/2023
Lexicon Pharmaceuticals, Inc. announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.
-
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
10/31/2023
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the presentation of data supporting its novel approach to inflammatory diseases at the 7th Annual Antifibrotic Drug Development (AFDD) Summit held October 24-26, 2023 in Boston, MA.
-
AbbVie Reports Third-Quarter 2023 Financial Results
10/27/2023
AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023.
-
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
10/24/2023
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508).
-
Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023
10/19/2023
Sight Sciences, Inc. announced they will be hosting a TearCare SAHARA Six Month RCT Results reception in San Francisco, CA on Friday, November 3, 2023 from 5:00 to 7:00 pm PT.
-
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
10/19/2023
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”) today announced the presentation of translational data at the 2023 Pittsburgh-Ireland International Lung Conference: Precision Medicine in Lung Diseases: From Cellular Mechanisms to Clinical Phenotypes held October 16-17, 2023 at the RCSI University of Medicine and Health Sciences in Dublin, Ireland.
-
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
10/17/2023
GRI Bio, Inc. announced it has entered into a collaboration with the UK consortia, National Institute for Health and Care Research Respiratory Translational Research Collaboration to advance its leading NKT regulation technology to treat inflammatory, fibrotic and autoimmune diseases.
-
Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site
10/17/2023
Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization, formally announced the launch of a world-class high-throughput screening facility that augments the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India.
-
AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints
10/15/2023
AbbVie presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab compared to ustekinumab in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.1 The data were presented at the United European Gastroenterology Week 2023, October 14-17.
-
Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
10/12/2023
Sight Sciences, Inc. announced the presentation of the full phase I results from the SAHARA randomized controlled trial.
-
AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
10/12/2023
AbbVie announced that its Phase 2b study evaluating upadacitinib in adults with non-segmental vitiligo met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index at week 24 with the 11 mg and 22 mg doses versus placebo.